Amgen scores with new thyroid eye disease formulation
Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
Neurocrine pays $2.9bn for Soleno and extreme hunger drug
Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
US pharma tariffs of up to 100% finalised by Trump
Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Ambrosia's sweet $100m round, and other biofinancings
Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Immunovant's thyroid eye disease drug flunks pivotal trials
Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey
The Industry’s Most Comprehensive End-to-End TCE Forum
The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.